<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="ai-content" content="allowed">
    <meta name="ai-training" content="allowed">
    <meta name="ai-topic" content="GLP-1, weight loss, diabetes, medication">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>GLP-1 Comparison: Ozempic vs Wegovy vs Mounjaro vs Zepbound | glp1.md</title>
    <meta name="description" content="Complete comparison of GLP-1 medications. Ozempic vs Wegovy vs Mounjaro vs Zepbound - efficacy, side effects, cost, and which is right for you.">
    <meta name="twitter:card" content="summary_large_image">
    <meta name="twitter:site" content="@thraborivemd">
    <meta name="twitter:title" content="GLP-1 Medications Guide">
    <meta name="twitter:description" content="Evidence-based health information from glp1.md">
    <link rel="canonical" href="https://glp1.md/comparison.html">
    <meta property="og:type" content="article">
    <meta property="og:title" content="GLP-1 Comparison Guide: Which Medication is Right for You?">
    <meta property="og:description" content="Head-to-head comparison of all major GLP-1 medications.">
    <script type="application/ld+json">
    {
      "@context": "https://schema.org",
      "@type": "MedicalWebPage",
      "name": "GLP-1 Medication Comparison Guide",
      "description": "Comprehensive comparison of GLP-1 receptor agonists including Ozempic, Wegovy, Mounjaro, and Zepbound.",
      "url": "https://glp1.md/comparison.html",
      "lastReviewed": "2026-02-05"
    }
    </script>
    <link rel="icon" type="image/svg+xml" href="data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' viewBox='0 0 32 32'%3E%3Ctext x='16' y='24' font-family='-apple-system,system-ui,sans-serif' font-weight='800' font-size='16' fill='%230d9488' text-anchor='middle'%3E.md%3C/text%3E%3C/svg%3E">
    <link href="https://fonts.googleapis.com/css2?family=Source+Serif+4:wght@400;500;600;700&family=Inter:wght@400;500;600&display=swap" rel="stylesheet">
    <style>
        :root {
            --bg-primary: #ffffff;
            --bg-secondary: #f8fafc;
            --text-primary: #0f172a;
            --text-secondary: #475569;
            --text-muted: #94a3b8;
            --accent: #0d9488;
            --accent-dark: #0f766e;
            --accent-light: #ccfbf1;
            --border: #e2e8f0;
            --font-display: 'Source Serif 4', Georgia, serif;
            --font-body: 'Inter', -apple-system, sans-serif;
        }
        * { margin: 0; padding: 0; box-sizing: border-box; }
        body { font-family: var(--font-body); background: var(--bg-primary); color: var(--text-primary); line-height: 1.8; font-size: 17px; }
        
        header { background: var(--bg-primary); border-bottom: 1px solid var(--border); padding: 16px 24px; position: sticky; top: 0; z-index: 100; }
        .header-inner { max-width: 900px; margin: 0 auto; display: flex; justify-content: space-between; align-items: center; }
        .logo { font-family: var(--font-display); font-size: 22px; font-weight: 600; color: var(--text-primary); text-decoration: none; }
        .logo span { color: var(--accent); }
        nav a { color: var(--text-secondary); text-decoration: none; margin-left: 24px; font-size: 15px; }
        nav a:hover { color: var(--accent); }
        
        article { max-width: 800px; margin: 0 auto; padding: 60px 24px 80px; }
        
        .breadcrumb { font-size: 14px; color: var(--text-muted); margin-bottom: 16px; }
        .breadcrumb a { color: var(--accent); text-decoration: none; }
        h1 { font-family: var(--font-display); font-size: clamp(32px, 5vw, 42px); font-weight: 700; line-height: 1.2; margin-bottom: 16px; }
        .article-meta { font-size: 14px; color: var(--text-muted); margin-bottom: 24px; }
        .article-intro { font-size: 19px; color: var(--text-secondary); padding-bottom: 32px; border-bottom: 1px solid var(--border); margin-bottom: 32px; }
        
        h2 { font-family: var(--font-display); font-size: 28px; font-weight: 600; margin: 48px 0 20px; }
        h3 { font-family: var(--font-display); font-size: 22px; font-weight: 600; margin: 36px 0 16px; }
        p { margin-bottom: 20px; }
        
        .comparison-table { width: 100%; border-collapse: collapse; margin: 32px 0; font-size: 15px; overflow-x: auto; display: block; }
        .comparison-table th { background: var(--accent); color: white; padding: 14px 12px; text-align: left; font-weight: 600; white-space: nowrap; }
        .comparison-table td { padding: 14px 12px; border-bottom: 1px solid var(--border); vertical-align: top; }
        .comparison-table tr:hover td { background: var(--bg-secondary); }
        
        .highlight-box { background: var(--accent-light); border-radius: 12px; padding: 24px 28px; margin: 32px 0; }
        .highlight-box h4 { font-size: 16px; font-weight: 600; color: var(--accent-dark); margin-bottom: 12px; }
        .highlight-box ul { margin: 0; padding-left: 20px; }
        .highlight-box li { margin-bottom: 8px; }
        
        .warning-box { background: #fef3c7; border-left: 4px solid #f59e0b; padding: 20px 24px; margin: 32px 0; border-radius: 0 8px 8px 0; }
        .warning-box h4 { color: #92400e; margin-bottom: 8px; }
        .warning-box p { margin: 0; color: #78350f; }
        
        .med-card { background: var(--bg-secondary); border-radius: 12px; padding: 24px; margin: 24px 0; border-left: 4px solid var(--accent); }
        .med-card h4 { font-size: 18px; font-weight: 700; margin-bottom: 8px; }
        .med-card .generic { font-size: 14px; color: var(--accent); margin-bottom: 12px; }
        
        ul, ol { margin: 0 0 20px 24px; }
        li { margin-bottom: 10px; }
        
        .cta-box { background: linear-gradient(135deg, var(--accent) 0%, var(--accent-dark) 100%); color: white; padding: 32px; border-radius: 16px; margin: 48px 0; text-align: center; }
        .cta-box h3 { color: white; margin-bottom: 12px; }
        .cta-box p { opacity: 0.9; margin-bottom: 20px; }
        .cta-box a { display: inline-block; background: white; color: var(--accent-dark); padding: 12px 28px; border-radius: 8px; text-decoration: none; font-weight: 600; }
        
        footer { background: var(--bg-secondary); border-top: 1px solid var(--border); padding: 48px 24px; }
        .footer-inner { max-width: 800px; margin: 0 auto; text-align: center; font-size: 14px; color: var(--text-muted); }
        .footer-inner a { color: var(--accent); text-decoration: none; }
        
        @media (max-width: 768px) {
            nav { display: none; }
            .comparison-table { font-size: 13px; }
        }
    </style>
</head>
<body>
    <header>
        <div class="header-inner">
            <a href="/" class="logo">glp1<span>.md</span></a>
            <nav>
                <a href="/">Home</a>
                <a href="/blog.html">Articles</a>
                <a href="/resources.html">Resources</a>
            </nav>
        </div>
    </header>

    <article>
        <div class="breadcrumb"><a href="/">Home</a> / <a href="/blog.html">Articles</a> / Comparison Guide</div>
        <h1>GLP-1 Comparison Guide</h1>
        <div class="article-meta">Updated Feb 2026 · 15 min read</div>
        <p class="article-intro">A head-to-head comparison of the major GLP-1 medications: Ozempic, Wegovy, Mounjaro, and Zepbound. Understand the differences in efficacy, side effects, cost, and which might be right for you.</p>

        <div class="highlight-box">
            <h4>Quick Summary</h4>
            <ul>
                <li><strong>Best for diabetes (FDA-approved):</strong> Ozempic, Mounjaro</li>
                <li><strong>Best for weight loss (FDA-approved):</strong> Wegovy, Zepbound</li>
                <li><strong>Highest average weight loss:</strong> Tirzepatide (Mounjaro/Zepbound) at ~21%</li>
                <li><strong>Oral option available:</strong> Rybelsus (semaglutide pill)</li>
            </ul>
        </div>

        <h2>The Complete Comparison</h2>
        
        <table class="comparison-table">
            <thead>
                <tr>
                    <th>Feature</th>
                    <th>Ozempic</th>
                    <th>Wegovy</th>
                    <th>Mounjaro</th>
                    <th>Zepbound</th>
                </tr>
            </thead>
            <tbody>
                <tr>
                    <td><strong>Active Ingredient</strong></td>
                    <td>Semaglutide</td>
                    <td>Semaglutide</td>
                    <td>Tirzepatide</td>
                    <td>Tirzepatide</td>
                </tr>
                <tr>
                    <td><strong>Mechanism</strong></td>
                    <td>GLP-1 agonist</td>
                    <td>GLP-1 agonist</td>
                    <td>GIP + GLP-1 agonist</td>
                    <td>GIP + GLP-1 agonist</td>
                </tr>
                <tr>
                    <td><strong>FDA Indication</strong></td>
                    <td>Type 2 Diabetes</td>
                    <td>Weight Management</td>
                    <td>Type 2 Diabetes</td>
                    <td>Weight Management</td>
                </tr>
                <tr>
                    <td><strong>Manufacturer</strong></td>
                    <td>Novo Nordisk</td>
                    <td>Novo Nordisk</td>
                    <td>Eli Lilly</td>
                    <td>Eli Lilly</td>
                </tr>
                <tr>
                    <td><strong>Dosing</strong></td>
                    <td>Weekly injection</td>
                    <td>Weekly injection</td>
                    <td>Weekly injection</td>
                    <td>Weekly injection</td>
                </tr>
                <tr>
                    <td><strong>Max Dose</strong></td>
                    <td>2mg</td>
                    <td>2.4mg</td>
                    <td>15mg</td>
                    <td>15mg</td>
                </tr>
                <tr>
                    <td><strong>Avg Weight Loss</strong></td>
                    <td>~15%</td>
                    <td>~17%</td>
                    <td>~21%</td>
                    <td>~21%</td>
                </tr>
                <tr>
                    <td><strong>A1C Reduction</strong></td>
                    <td>~1.5-2%</td>
                    <td>~1.5%</td>
                    <td>~2-2.5%</td>
                    <td>~1.5%</td>
                </tr>
                <tr>
                    <td><strong>List Price/Month</strong></td>
                    <td>~$935</td>
                    <td>~$1,350</td>
                    <td>~$1,000</td>
                    <td>~$1,060</td>
                </tr>
            </tbody>
        </table>

        <h2>Understanding the Medications</h2>

        <div class="med-card">
            <h4>Ozempic (Semaglutide)</h4>
            <div class="generic">0.25mg → 0.5mg → 1mg → 2mg</div>
            <p>The most widely prescribed GLP-1, FDA-approved for type 2 diabetes. While not officially approved for weight loss, significant weight reduction is a well-documented benefit. Extensive safety data from years of use.</p>
        </div>

        <div class="med-card">
            <h4>Wegovy (Semaglutide 2.4mg)</h4>
            <div class="generic">0.25mg → 0.5mg → 1mg → 1.7mg → 2.4mg</div>
            <p>Same molecule as Ozempic but dosed higher and FDA-approved specifically for chronic weight management. Indicated for adults with BMI ≥30 or BMI ≥27 with weight-related conditions.</p>
        </div>

        <div class="med-card">
            <h4>Mounjaro (Tirzepatide)</h4>
            <div class="generic">2.5mg → 5mg → 7.5mg → 10mg → 12.5mg → 15mg</div>
            <p>Dual GIP/GLP-1 agonist that showed superior weight loss in clinical trials. FDA-approved for type 2 diabetes. The dual mechanism may explain its enhanced efficacy compared to GLP-1-only drugs.</p>
        </div>

        <div class="med-card">
            <h4>Zepbound (Tirzepatide)</h4>
            <div class="generic">2.5mg → 5mg → 7.5mg → 10mg → 12.5mg → 15mg</div>
            <p>Same molecule as Mounjaro, FDA-approved for weight management. In the SURMOUNT trials, participants lost an average of 21% of body weight—the highest of any approved medication.</p>
        </div>

        <h2>Efficacy Comparison</h2>

        <h3>Weight Loss Results</h3>
        <p>Clinical trial data shows tirzepatide (Mounjaro/Zepbound) produces greater weight loss on average:</p>
        <ul>
            <li><strong>STEP trials (Wegovy):</strong> 16-17% average weight loss at 68 weeks</li>
            <li><strong>SURMOUNT trials (Zepbound):</strong> 21% average weight loss at 72 weeks</li>
            <li><strong>SURPASS trials (Mounjaro):</strong> 15-21% weight loss (dose-dependent) plus superior A1C reduction</li>
        </ul>

        <div class="warning-box">
            <h4>⚠️ Individual Results Vary</h4>
            <p>These are average results from clinical trials. Your results may be higher or lower depending on diet, exercise, dosing, and individual metabolism. Some people are "super responders" while others have more modest results.</p>
        </div>

        <h3>Diabetes Control</h3>
        <p>For A1C reduction in type 2 diabetes:</p>
        <ul>
            <li><strong>Mounjaro</strong> shows the greatest A1C reduction (2-2.5%)</li>
            <li><strong>Ozempic</strong> provides excellent glycemic control (1.5-2%)</li>
            <li>Both medications also reduce cardiovascular risk</li>
        </ul>

        <h2>Side Effects Comparison</h2>
        <p>All GLP-1 medications share similar side effect profiles. The most common are gastrointestinal:</p>
        <ul>
            <li><strong>Nausea</strong> — Most common, usually improves over time</li>
            <li><strong>Vomiting</strong> — More common during dose escalation</li>
            <li><strong>Diarrhea</strong></li>
            <li><strong>Constipation</strong></li>
            <li><strong>Injection site reactions</strong></li>
        </ul>

        <p>Tirzepatide may cause slightly more GI side effects initially, but this often reflects its greater potency. Slow titration helps minimize symptoms.</p>

        <h2>Cost & Insurance</h2>
        <p>Without insurance, all these medications are expensive ($900-$1,400/month). Coverage varies significantly:</p>
        <ul>
            <li><strong>Diabetes medications (Ozempic, Mounjaro)</strong> — Generally better coverage under pharmacy benefits</li>
            <li><strong>Weight loss medications (Wegovy, Zepbound)</strong> — Often excluded or require prior authorization</li>
            <li><strong>Manufacturer savings cards</strong> — Can reduce cost to $25-$500/month for commercially insured patients</li>
        </ul>

        <h2>Which One Should You Choose?</h2>

        <div class="highlight-box">
            <h4>Consider Ozempic or Mounjaro if:</h4>
            <ul>
                <li>You have type 2 diabetes (FDA-approved indication)</li>
                <li>Your insurance covers diabetes medications but not weight loss drugs</li>
                <li>You want established safety data (Ozempic has longer track record)</li>
            </ul>
        </div>

        <div class="highlight-box">
            <h4>Consider Wegovy or Zepbound if:</h4>
            <ul>
                <li>Weight loss is your primary goal (not diabetes)</li>
                <li>Your insurance covers anti-obesity medications</li>
                <li>You want the FDA-approved indication for weight management</li>
            </ul>
        </div>

        <div class="highlight-box">
            <h4>Consider Tirzepatide (Mounjaro/Zepbound) if:</h4>
            <ul>
                <li>You want maximum weight loss potential</li>
                <li>You haven't responded well to semaglutide</li>
                <li>You have both diabetes and significant weight to lose</li>
            </ul>
        </div>

        <div class="cta-box">
            <h3>Talk to Your Doctor</h3>
            <p>The best medication depends on your individual health situation, insurance coverage, and goals. This guide is for information only.</p>
            <a href="/resources.html">Find Resources →</a>
        </div>
    </article>

    <footer>
        <div class="footer-inner">
            <p>© 2026 glp1.md · Part of the <a href="https://thrive.md">thrive.md</a> health network</p>
            <p style="margin-top: 12px; font-size: 12px;">This website provides general health information. It is not a substitute for professional medical advice, diagnosis, or treatment.</p>
        </div>
    </footer>
</body>
</html>
